Fresh analysis suggests that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop traditional lifestyle plans.
Research printed in a prominent health publication points out that while overweight people often shed about a fifth of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month once they quit.
"Users buying such medications need to be cognizant of the potential of quick weight regain when the therapy ends," stated expert Dr. Susan Jebb.
That rate of regain means a return to original mass within about a year and a half.
Comparing Approaches
The study, which reviewed 37 of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.
Scientists emphasize that individuals who lose weight through dieting usually experience a slower creep back—perhaps 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Nutrition scientists suggest the mode of action of the jabs accounts for the amplified regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication means hunger is no longer kept in check, making excessive eating a significant risk."
A Chronic Disease?
Health authorities suggest the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Professionals argue that, given the significant potential of relapse, the treatment might need to be ongoing.
This perspective is reinforced by pharmaceutical companies, who say that the results "highlight the persistent nature of excess weight," similar to managing diseases like diabetes.
User Experiences
Users who have stopped the medication explain a intense resurgence of appetite.
"I experienced something activating and you're instantly starving," recalled a patient.
This difficulty is worsened if patients have not established lasting lifestyle or habit changes during treatment.
Growing Interest
Figures indicate that millions of people in the UK have used weight-loss jabs in the past year, with demand remaining high.
- Use is more common among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians caution that while these medications are potent agents for weight loss, they are not a standalone solution and lasting health benefits relies on integrated lifestyle support.
